Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse

References

• Aouizerate B, Guehl D, Cuny E, et al. Pathophysiology of obsessive-compulsive disorder. A necessary link between phenomenology, neuropsychology, imagery and physology. Prog Neurobiol 2004; 72: 195–221
   PubMed Web of Science ®Google Scholar
• Bottas A, Cooke RG, Richter MA. Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia?. J Psychiatr Neurosci 2005; 30: 187–193
   PubMed Web of Science ®Google Scholar
• Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The neuopsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioral inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005; 29: 399–419
   PubMed Web of Science ®Google Scholar
• Curran HV. Is MDMA (“Ecstasy”) neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 2000; 42: 34–41
   PubMed Web of Science ®Google Scholar
• Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185: 196–204
   PubMed Web of Science ®Google Scholar
• Goñi-Allo B, Ramos M, Hervias I, Lasheras B, Aguirre N. Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/malnate combination: implications for serotonin/ dopamine interactions. J Psychopharmacol 2006; 20: 245–256
   PubMedGoogle Scholar
• Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methylenedioxymethamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 2006; 101: 348–361
   PubMed Web of Science ®Google Scholar
• Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmachology and clinical pharmachology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 2003; 55: 463–508
   PubMed Web of Science ®Google Scholar
• Huizinik AC, Ferdinand RF, Van der Ende J, Verhulst FC. Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. Br Med J 2006; 332: 825–828
   PubMedGoogle Scholar
• Kalant H. The pharmachology and toxicology of “ecstasy” (MDMA) and related drugs. Can Med Assoc J 2001; 165: 917–928
   PubMed Web of Science ®Google Scholar
• Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 2000; 55: 294–296
   PubMedGoogle Scholar
• Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet 2004; 364: 453–461
   PubMed Web of Science ®Google Scholar
• Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen HU. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 2002; 68: 195–207
   PubMed Web of Science ®Google Scholar
• McCann UD, Szabo Z, Scheffe U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet 1998; 352: 1433–1437
   PubMed Web of Science ®Google Scholar
• McGuire P, Cope H, Fahy TA. Diversity of psychopatology associated with use of 3,4-methylenedioxymethamphetamine (“Ecstasy”). Br J Psychiatry 1994; 165: 391–395
   PubMed Web of Science ®Google Scholar
• Micallef J, Blin O. Neurobiology and clinical pharmachology of obsessive-compulsive disorder. Clin Neuropharmacol 2001; 24: 191–207
   PubMed Web of Science ®Google Scholar
• Parrott AC, Milani RM, Parmar R, Turner JJD. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001; 159: 77–82
   PubMed Web of Science ®Google Scholar
• Pfohl B, Blum N, Zimmerman M. Structured interview for DSM-IV personality. American Psychiatric Press, Washington, DC 1997
   Google Scholar
• Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophreina. Clinical characteristic and treatment. CNS Drugs 2004; 18: 989–1010
   PubMed Web of Science ®Google Scholar
• Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA (“ecstasy”) consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 1998; 52: 85–90
   PubMed Web of Science ®Google Scholar
• Schifano F. Potential human neurotoxicity of MDMA (“Ecstasy”): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000; 42: 25–33
   PubMed Web of Science ®Google Scholar
• Shih RA, Belmonte PL, Zandi PP. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry 2004; 16: 260–283
   PubMed Web of Science ®Google Scholar
• Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ., Siever LJ. The borderline diagnosis I: Psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002; 51: 936–950
   PubMed Web of Science ®Google Scholar
• Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105–115
   PubMed Web of Science ®Google Scholar
• Zohar J, Chropa M, Sasson Y, Amiaz R, Amital D. Obsessive-compulsive disorder: serotonin and beyond. World J Biol Psychiatry 2000; 1: 92–100
   PubMedGoogle Scholar